Financings Of The Fortnight: Despite Venture Capital Fundraising Struggles, Deals Continue
This article was originally published in The Pink Sheet Daily
Big venture rounds for Flexion and Lux Biosciences highlight the last two weeks' financing activity.
You may also be interested in...
The ophthalmology specialist's inside round could take it through to launch of its lead product--or act as leverage in deal negotiations.
Existing and new investors are drawn by the potential of a compound that would compete with statins in the dyslipidemia market.
Ophthalmology has long been a bright spot for venture investors given the potential market size, health care burden, and high unmet medical need associated with many eye diseases. Based on a recent analysis by Start-Up magazine, there is no sign that trend is diminishing. Using Elsevier's Strategic Transactions database, Start-Up found that private backers have poured nearly $1.8 billion into 58 ophthalmology start-ups since 1999, with the money split nearly 50/50 in terms of device and drug investments. This trend is likely to accelerate as a number of new acquirers emerge to play in what was once a niche area.